Targeted Medicine for Better Health

C3J Therapeutics is a clinical-stage biotechnology company based in Los Angeles, California.

C3J Therapeutics is focused on improving human health through the development and commercialization of targeted, or pathogen-specific, antimicrobials that treat and prevent diseases caused by microbial dysbiosis. A disrupted or imbalanced microbial ecology due to disease or broad-spectrum antibiotic use can result in negative clinical consequences and prolonged debilitating infections. Recent understandings of the human microbiome have illustrated the importance of a healthy and balanced microbial ecosystem and the link to improvements in human disease outcomes and disease risk.

C3J Therapeutics refers to the targeted compounds as STAMPs: Specifically Targeted Antimicrobial Peptides.

The STAMP Platform Technology was pioneered in the lab of Dr. Wenyuan Shi, Chairman of Oral Biology at the University of California Los Angeles (UCLA) School of Dentistry and Professor of Microbiology, Immunology & Molecular Genetics at the UCLA David Geffen School of Medicine.